Home・Список акций・Vaxart Inc

Vaxart Inc

Закрыт

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

Макс.

Ключевые показатели
By Trading Economics
Доход	-19M -13M
Продажи	-12M 27M
P/E Средняя по отрасли	3 56.659
Прибыль на акцию	-0.06
Рентабельность продаж	-49.638
Сотрудники	65
EBITDA	-19M -12M

Дивиденды
By Acuity
Следующий отчет о доходах	12 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-19M 124M
Предыдущая цена открытия	0
Предыдущая цена закрытия	0

Vaxart Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

6 сент. 2026 г., 23:51 UTC

ECB President Lagarde's Upcoming Speech on September 9, 2026, Expected to Address Interest Rates and Inflation Amidst Euro Area Economic Uncertainties.

6 сент. 2026 г., 23:51 UTC

Correlated Moves

Avalanche is trading higher, boosted by strong performance in correlated assets like Ethereum. It is currently 8.96% above its 20-day moving average.

6 сент. 2026 г., 23:41 UTC

Investors Brace for September 11 CPI Release Amid Rising Inflation Concerns and Economic Uncertainties

6 сент. 2026 г., 23:41 UTC

Investors Brace for Key CPI Release on September 11, Anticipating Impact on Inflation Trends and Market Dynamics.

6 сент. 2026 г., 23:41 UTC

U.S. Inflation Rate Expected to Stabilize at 3.4% Amid Market Caution and Potential Fed Interest Rate Hikes

6 сент. 2026 г., 23:41 UTC

U.S. Core Inflation Rate Expected at 2.4% Amid Rising Market Volatility and Anticipated Fed Rate Hike Discussions

6 сент. 2026 г., 23:41 UTC

Core Inflation Rate Expected to Rise 0.2% in August, Sparking Optimism Among Traders Ahead of September Release

6 сент. 2026 г., 23:41 UTC

U.S. Inflation Rate Expected to Rise by 0.4% in August, Heightening Concerns Over Interest Rate Hikes Amid Strong Job Growth

6 сент. 2026 г., 23:31 UTC

U.S. Core Producer Prices Expected to Rise 0.3% in August Amid Inflation Concerns and Potential Fed Rate Hikes

6 сент. 2026 г., 23:21 UTC

U.S. Producer Price Inflation Expected to Rise 0.3% Amid Caution Over Potential Fed Rate Hikes

6 сент. 2026 г., 23:11 UTC

Euro Area's Deposit Facility Rate Expected to Rise to 0.025% Amid Investor Anticipation of Economic Catalysts

6 сент. 2026 г., 22:41 UTC

Australia's Westpac Consumer Confidence report set for September 8, 2026, shows cautious optimism amid inflation concerns and rising investor confidence.

6 сент. 2026 г., 22:31 UTC

Mexican Inflation Rate Expected to Continue Declining Trend Ahead of September 9 Release, Boosting Market Optimism.

6 сент. 2026 г., 22:31 UTC

Mexico's Inflation Rate Release on September 9, 2026 Expected to Influence Market Dynamics Amid Global Economic Sentiment.

6 сент. 2026 г., 22:31 UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, amid mixed market expectations and rising optimism following increased buying activity.

6 сент. 2026 г., 22:21 UTC

MBA 30-Year Mortgage Rate Release on September 9, 2026, Expected to Show Continued Upward Pressure Amid Inflation and Fed Policy Concerns.

6 сент. 2026 г., 22:11 UTC

Brazil's Central Bank to Provide Key Insights on Monetary Policy Direction in Upcoming Interest Rate Readout Amid Market Uncertainty

6 сент. 2026 г., 22:01 UTC

Japan's GDP Growth Forecasted at +1.1% for Q2 2026 Amid Cautious Optimism in Economic Recovery

6 сент. 2026 г., 22:01 UTC

Japan's GDP Growth Rate Expected at +0.4% Amidst Rising Market Confidence and Global Economic Discussions

6 сент. 2026 г., 21:51 UTC

Turkey's Central Bank Expected to Maintain 37% Interest Rate Amid Inflation Concerns Ahead of September Decision.

6 сент. 2026 г., 21:51 UTC

UK Housing Market Faces Continued Pressure as RICS House Price Balance Forecast Improves Slightly to -0.28% Amid Weak Buyer Demand

6 сент. 2026 г., 21:31 UTC

South Korea's August 2026 unemployment rate release on September 8 sparks cautious optimism amid recent job gains and inflationary pressures.

6 сент. 2026 г., 21:11 UTC

UK Retail Sales Monitor YoY for August 2026 Expected to Show Modest 1.2% Increase Amid Cautious Consumer Sentiment and Economic Challenges

6 сент. 2026 г., 21:01 UTC

Spain's Consumer Confidence report on September 8, 2026, shows rising optimism with an index increase to 81.2 amid recovering market sentiment and geopolitical concerns.

6 сент. 2026 г., 21:01 UTC

Cautious Market Sentiment Ahead of South Africa's Q2 GDP Growth Rate Release Amid Global Economic Fluctuations

6 сент. 2026 г., 21:01 UTC

South Africa's GDP Growth Rate Release on September 8, 2026 Sparks Market Optimism Amid Global Economic Factors.

6 сент. 2026 г., 20:21 UTC

Japan's Current Account data set for release on September 7, 2026, forecasts a surplus of JPY 2.87 trillion amid cautious investor sentiment due to historical volatility in outcomes.

6 сент. 2026 г., 19:01 UTC

API Crude Oil Stock Change Data Release on September 9, 2026, Expected to Reflect Volatile U.S. Inventory Trends Amid Geopolitical Tensions and OPEC+ Production Stability.

6 сент. 2026 г., 18:51 UTC

Italy's Industrial Production Expected to Rise 0.3% in July Amidst Recent Declines and Economic Concerns

6 сент. 2026 г., 18:31 UTC

France's Industrial Production Expected to Rise 0.3% in July Amid Economic Uncertainty

Сравнение c конкурентами

Изменение цены

Vaxart Inc Прогноз

Консенсус по рейтингу

By TipRanks

0 ratings

Покупка

Удержание

Продажа

Основано на мнении 0 аналитиков, присваивавших рейтинги акциям Vaxart Inc – Данные за последние 3 месяца.

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.